
【CLAIMS】

【Claim 1】

Use of a compound of Formula 1, an optical isomer thereof, or a pharmaceutically acceptable salt thereof, in the manufacture of ~~a or~~ a pharmaceutical composition for treating type II diabetes in a patient who has been administrated a sulfonylurea-based drug as an agent for promoting insulin secretion and suffers from pancreatic beta cell damage due to long-term administration of a sulfonylurea-based drug~~, but of which the blood glucose is not regulated in a normal manner by using the agent for promoting insulin secretion~~,

[Formula 1]



.

【Claim 2】

The use according to claim 1, wherein the patient who suffers from pancreatic beta cell damage due to long-term administration of a sulfonylurea-based drug ~~of which the blood glucose is not regulated in a normal manner by using an agent for promoting insulin secretion~~ is a patient who has been co-administered a sulfonylurea-based drug as the agent for promoting insulin secretion and a biguanide-based drug as other hypoglycemic agents.

【Claim 3】

The use according to claim 1, wherein the pharmaceutical composition is to be administered either alone or in combination with other drugs for treating type II diabetes.

【Claim 4】

The use according to claim 1, wherein the pharmaceutical composition is to be administered in combination with a biguanide-based drug.